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The	 microtubule-associated	 protein	 tau	 and	 its	 pathological	 modification	 constitute	 the	
central	 pathology	 of	 various	 human	 neurodegenerative	 diseases,	 including	 Alzheimer’s	
disease	 (AD),	 collectively	 termed	 ‘tauopathies’.	 Abundant	 hyperphosphorylation	 and	
aggregation	 of	 tau	 is	 a	 disease-defining	 hallmark,	 yet	 the	 underlying	 pathogenic	 and	
pathophysiological	 processes	 have	 remained	 only	 partly	 understood.	 In	 addition,	 protein	
fragmentation	 is	 a	 frequently	 observed	 phenomenon	 in	 the	 course	 of	 various	
neurodegenerative	 diseases;	 however,	 the	 contribution	 of	 tau	 fragmentation	 to	 the	
pathogenesis	of	tauopathies	is	still	a	matter	of	debate.	
In	our	novel	 inducible	mouse	model,	co-expression	of	truncated	and	full-length	human	tau	
provokes	 axonal	 transport	 failure,	 mitochondrial	 mislocalization,	 disruption	 of	 the	 Golgi	
apparatus	and	dysregulation	of	synaptic	proteins	associated	with	extensive	nerve	cell	loss	and	
a	severe	neurological	phenotype	as	early	as	3	weeks	of	age.	Of	note,	this	was	paralleled	only	
by	 the	 formation	 of	 soluble	 oligomeric	 tau	 species,	 and	 no	 insoluble	 filamentous	 tau	
aggregates;	therewith,	identifying	oligomeric	tau	species	as	toxic	key	players	in	tau	pathology.	
Despite	continuous	full-length	tau	expression,	mice	recovered	from	the	neurotoxic	insult	once	
truncated	 tau	 expression	was	 halted.	 The	 induction	of	 drastic	 but	 reversible	 neurotoxicity	



































































































































the	affected	brain	 regions,	 linking	a	particular	disease-type	 to	 its	predominant	phenotype.	
Unique	 pathological	 conformers	 or	 misfolded	 proteins	 with	 modified	 native	 physiological	
properties	 are	 integral	 parts	 and	 the	 core	 concept	 of	 diverse	 human	 ’proteinopathies’;	




The	 pathological	 conformation	 and	 subsequent	 aggregation	 of	 proteins	 is	 not	 solely	






proteasome	 system	 (UPS)	 and	 autophagy-lysosomal	 pathways,	 as	major	mechanisms	 for	
degradation	 of	 numerous	 proteins,	 have	 been	 found	 to	 be	 relevant	 for	 the	 genesis	 and	
progression	of	several	neurodegenerative	diseases	(Keller	et	al.,	2000;	Nixon,	2007;	reviewed	
in	Oddo,	2008;	Pickford	et	al.,	2008).	Indeed,	various	aggregated	proteins	as	well	as	induction	
of	 proteasome	 inhibitors	 have	 been	 shown	 to	 interfere	 with	 the	 highly	 regulated	 cell	
physiology	by	 impairing	UPS	function	(Bence	et	al.,	2001;	David	et	al.,	2002;	Gregori	et	al.,	
1995;	Keck	et	al.,	2003;	Lee	et	al.,	2010;	Snyder	et	al.,	2003;	Tseng	et	al.,	2007).	In	contrast	to	
their	 ability	 of	 non-aggregated	 and	 soluble	 unfolded	 protein	 degradation,	 oligomeric	 or	
aggregated	 species	 are	 rather	 inaccessible	 to	 the	 catalytic	 core	 of	 the	 UPS;	 an	 efficient	
autophagy-lysosomal	machinery	 is	needed	to	degrade	aggregation-prone	proteins,	 thereby	
preventing	neuropathological	processes	(Anglade	et	al.,	1997;	Boland	et	al.,	2008;	Qin	et	al.,	
2003).	 In	 addition,	 stimulation	of	 autophagy	has	been	 shown	 to	 reduce	 the	 generation	of	
pathological	protein	inclusions	in	nerve	cells	(Ozcelik	et	al.,	2013;	Schaeffer	et	al.,	2012;	Wang	
et	al.,	2009b).	
Aside	 further	 neurodegenerative	 disease-causing	 processes	 such	 as	 glutamate-induced	
exocytoxic	 insults	 (Marchetti	 et	 al.,	 2004)	 or	 neuroinflammatory	 processes	 (Harry	 et	 al.,	
2000),	 another	 event	 detrimental	 to	 neuronal	 homeostasis	 is	 mitochondrial	 injury	 by	
neurodegeneration-associated	proteins;	mitochondrial	dysfunction,	i.e.	in	terms	of	impaired	
mitochondrial	 trafficking	 inside	neurons	 (Rui	et	al.,	2010;	Rui	et	al.,	2006)	or	alterations	 in	
mitochondrial	dynamics	 (Wang	et	al.,	2009a),	 is	crucially	 linked	to	oxidative	and	nitrosativ	



















not	 always	 evident	 and	 the	 neurotoxic	 potential	 of	 cleavage	 products	 is	 still	 a	 matter	 of	
debate.	Cleavage	occurs	at	multiple	sites	of	single	large	proteins	with	researchers	consider	the	
question	 of	 a	 causal	 relationship	 between	 protein	 fragmentation	 and	 disease,	 or	whether	
fragmentation	 just	 being	 an	 epiphenomenon.	 Protein	 aggregates	 in	 neurodegenerative	
disorders	may	either	consist	of	(I)	fragments	alone	derived	from	larger	precursor	proteins:	as	






thrombin	 (Arai	 et	 al.,	 2005),	 cathepsins	 (Kenessey	 et	 al.,	 1997)	 and	 puromycin-sensitive	
aminopeptidase	(PSA)	(Sengupta	et	al.,	2006),	members	of	the	caspase	and	calpain	family	are	











(II)	 executioner	 caspases	 (caspases-3,	 6,	 and	 7)	 (Pop	 and	 Salvesen,	 2009).	 These	 caspase	
candidates	 are	 associated	 with	 programmed	 apoptotic	 cell	 death	 in	 various	









cleavage.	 Indeed,	 caspases-3	 (Metcalfe	 et	 al.,	 2012),	 caspase-6,	 and	 calpains	 are	 the	main	
enzymes	involved	in	tau	protein	fragmentation,	with	the	Asp421	being	the	most	prominent	
caspase	cleavage	site	(for	review	see	Avila,	2010;	Fasulo	et	al.,	2005;	Guillozet-Bongaarts	et	























profile	 of	 a	 vast	 number	 of	 neurodegenerative	 diseases.	 However,	 pathologically	 altered	
proteins	 including	 their	 characteristic	 structure	 and	 morphology	 remain	 to	 be	 the	 most	
prominent	entity.	Proteins	that	undergo	fragmentation	in	parallel	to	pathological	aggregation	




































Tau	 belongs	 to	 the	 natively	 unfolded	microtubule-associated	 protein	 family	 (MAP)	 and	 is	
abundant	in	the	central	and	peripheral	nervous	system.	In	the	1970s,	a	microtubule	binding	
activity	of	tau	protein	has	first	been	shown	by	Weingarten	et	al.,	who	isolated	a	heat	stable	
protein	most	abundantly	 found	 to	promote	microtubule	assembly	and	 stability	 in	 cell-free	
conditions	 (Weingarten	 et	 al.,	 1975).	 Microtubules	 are	 protein	 polymers	 and	 a	 major	
component	 of	 the	 cytoskeleton	 with	 an	 essential	 role	 in	 regulated	 motor-driven	 axonal	
transport.	 Later,	 evidence	 from	brains	of	patients	with	AD	 suggested	 that	 tau	 is	 actual	 an	
integral	part	of	the	pathology	in	neurodegenerative	disorders	(Goedert	et	al.,	1988;	Grundke-
Iqbal	et	al.,	1986;	Kondo	et	al.,	1988;	Kosik	et	al.,	1986;	Wischik	et	al.,	1988a).	Efforts	for	a	






(Binder	 et	 al.,	 1985).	 However,	 it	 also	 has	 been	 shown	 to	 be	 located	 in	 the	 dendritic	




way,	 being	 able	 to	 serve	 as	 a	 spacer	 between	 the	 individual	 components	 within	 the	
microtubule	network	(Chen	et	al.,	1992;	Frappier	et	al.,	1994).	Furthermore,	it	was	found	that	
this	region	appears	to	interact	with	membrane-binding	proteins	such	as	annexin	A2	(AnxA2)	


















1992).	Six	 isoforms	 of	 tau	 are	 expressed	 in	 the	 adult	 human	brain	 (Goedert	 et	 al.,	 1989).	
Produced	by	complex	alternative	mRNA	splicing	of	the	MAPT	gene	located	on	chromosome	
17q21.31,	each	isoform	differs	in	its	specific	representation	as	such	in	the	presence	or	absence	


















et	 al.,	 1994).	 The	 main	 physiological	 function	 of	 tau	 is	 stabilization	 of	 the	 microtubule	
network	 by	promoting	 the	polymerization	of	 tubulin	and	 thus	 the	maintenance	of	normal	
axonal	transport	(Bohm	et	al.,	1990;	Brandt	and	Lee,	1993;	Cleveland	et	al.,	1977;	Shahani	and	

















this	 way,	 mitochondria	 (Hollenbeck	 and	 Saxton,	 2005),	 lysosomes	 (Harada	 et	 al.,	 1998),	
peroxisomes		(Wali	et	al.,	2016)	and	various	other	organelles	can	be	localized	to	distinct	areas	
in	the	neuronal	realm	in	order	to	accomplish	their	very	own	function.	The	tight	binding	of	tau	
alters	 the	 intracellular	 traffic	 as	 well	 as	 ensures	 the	 dynamic	 instability	 of	 microtubules	
(Mitchison	 and	 Kirschner,	 1984;	 Trinczek	 et	 al.,	 1995).	 The	 latter	 is	 distinguished	 by	 their	
capability	 to	 switch	 between	 slow	 growth	 and	 rapid	 shrinking	 during	microtubule	 growth	
(Binder	 et	 al.,	 1985;	 Mitchison	 and	 Kirschner,	 1984).	 Aside	 from	 its	 predominant	
neurophysiological	 activity	 –	 binding	 to	 microtubule	 –	 numerous	 functions	 have	 been	
attributed	to	tau.	Among	them,	modulation	of	biochemical	cascades,	such	that	tau	can	act	as	



























that	 isolated	 tau	 molecules	 from	 healthy	 human	 brains	 contained	 roughly	 two	 moles	 of	















dephosphorylate	 tau	 in	 vitro	 (Wang	et	al.,	 1995;	Yamamoto	et	al.,	 1988);	moreover,	PP2A	
expression	and	activity	was	found	to	be	reduced	in	the	brains	of	AD	patients,	suggesting	that	








80	 potential	 phosphorylation	 sites	 and	 a	 disequilibrium	 in	 candidate	 protein	 kinase	 and	





















et	 al.,	 2005).	 Given	 that	 the	 aggregation	 of	 tau	 correlates	with	 its	 propensity	 for	 β-sheet	
structure,	an	altered	shape	of	tau	protein	by	proteolytic	fragmentation	potentially	affect	its	
aggregation	 capacity.	 The	 architecture	 of	 paired	 helical	 and	 straight	 filaments	 of	 AD	 is	






In	Alzheimer’s	disease,	 tau	 truncation	was	 found	 to	be	an	early	event	and	appears	before	
neurofibrillary	 tangle	 (NFT)	 formation	 albeit	 after	 hyperphophorylation	 of	 tau	 (Guillozet-
Bongaarts	et	al.,	2005;	Mondragon-Rodriguez	et	al.,	2008;	Rohn	et	al.,	2002;	Saito	et	al.,	2010).	
Various	 types	 of	 tau	 fragmentation	 have	 been	 reported	 in	 cells	 and	 brain	 tissue;	 cysteine	
proteases	 such	as	caspases	and	calpains	have	been	 implicated	 in	proteolysis	of	 tau	during	
apoptosis	 (Canu	et	 al.,	 1998).	 In	 vitro	 and	 in	 vivo	experiments	predicted	multiple	putative	







C-terminal	 domain	 of	 tau	 (Guo	 et	 al.,	 2004;	 Rissman	 et	 al.,	 2004;	 Zhang	 et	 al.,	 2009a).	










The	 term	 “Tauopathy”	 summarizes	 a	 heterogeneous	 group	 of	 disorders	 with	
hyperphosphorylated,	insoluble,	filamentous	tau	protein	inclusions	in	neurons	and	glial	cells	
(Spillantini	and	Goedert,	2013)	(Figure	1.4).	These	human	neurodegenerative	diseases	are	in	
most	 cases	 sporadic,	 and	 clinically	 characterized	 by	 dementia,	 often	 associated	 with	
movement	 impairment.	 Most	 frequent	 tauopathies	 include	 AD	 (see	 paragraph	 1.2.2.1),	
Progressive	 supranuclear	palsy	 (PSP)	 (Steele	et	al.,	 1964),	Corticobasal	degeneration	 (CBD)	
(Rebeiz	et	al.,	1968),	Pick’s	disease	(PiD)	(Constantinidis	et	al.,	1974),	Argyrophilic	grain	disease	
























and	TDP-43	 are	 increasingly	emerging	as	 considerable	 candidates	with	potential	 prion-like	
properties	(Figure	1.5).	In	case	of	potential	Aβ	seeding,	this	is	reflected	in	studies	on	mouse	









































The	 majority	 of	 neurodegenerative	 disorders	 is	 associated	 with	 pathological	 protein	
aggregation.	The	term	“proteinopathies”	has	therefore	been	established	for	these	diseases.	
The	mechanisms	underlying	protein	aggregation	 in	proteinopathies	has	 in	many	cases	only	
been	 partially	 understood.	 Different	 factors	 may	 eventually	 lead	 to	 pathological	 protein	
aggregation.	First	of	all,	an	 increased	aggregation	propensity	of	a	given	protein	can	 induce	
pathological	 folding	 and	 aggregation.	 Proteins	 can	 be	 rendered	 aggregation	 prone	 by	
patholocigal	 mutations,	 e.g.	 in	 the	 case	 of	 hereditary	 forms	 of	 proteinopathies,	 or	 by	
truncation.	In	sporadic	diseases,	factors	i.e.	decreased	protein	clearance,	e.g.	by	autophagy	
disruption,	 are	 furthermore	 suspected	 to	 be	 underlying	 the	 aggregation	 process.	 These	
processes	 involve	 protein	 cleavage	 and	 may	 thereby	 not	 only	 be	 beneficial	 by	 removing	
misfolding	proteins,	but	also	 indirectly	 contribute	 to	 render	 the	aggregation	propensity	by	
cutting	proteins	into	small	peptides	with	seed-like	character.	In	most	cases,	the	aggregating	
proteins	 are	 rather	 small,	 often	 derived	 of	 a	 precursor	 protein.	 All	 this	 points	 towards	 a	
unifying	 characteristic	 of	 protein	 cleavage	 as	 a	 key	 factor	 leading	 to	 aggregation	 prone	











(I) Tauopathy;	 including	 Alzheimer’s	 disease	 (AD),	 frontotemporal	 dementia	 and	























protein	 remnants,	 or	 contain	 co-aggregated	 full-length	 proteins	 and	 cleaved	 fragments	 in	
parallel.	 Cleavage	 derived	 species	 of	 the	most	 notable	 entities	 and	 their	 potential	 role	 in	
neurodegeneration	 will	 be	 addressed	 separately	 in	 the	 following	 paragraphs;	 a	 detailed	



















progression	 of	 AD	 (EOAD)	 (Tanzi,	 1999).	Mutations	 in	 genes	 coding	 for	 amyloid	 precursor	
protein	 (APP;	 located	 on	 chromosome	21;	 presenilin	 1	 (PS1;	 located	 on	 chromosome	14),	
presenilin	2	(PS2;	located	on	chromosome	1)	have	been	reported	in	FAD	(Goate	et	al.,	1991;	
Sherrington	et	al.,	1995).	
Alzheimer’s	 disease	 is	 a	 most	 probably	 heterogeneous	 neurodegenerative	 disorder.	 It	 is	





amyloid	 (Aβ;	 see	 paragraph	 1.2.2.2)	 plaques,	 vascular	 Aβ	 deposits	 (cerebral	 amyloid	
angiopathy;	CAA;	see	paragraph	1.2.3.)	and	intracellular	aggregates	of	tau	protein	(NFTs;	see	
paragraph	1.1.6)	(Alzheimer,	1906,	1907)	(Figure	1.6).	
Massive	 neuronal	 and	 dendritic	 loss	 is	 the	 primary	 cause	 of	 cortical	 atrophy	 during	 the	
progression	of	AD.	Atrophic	changes	results	in	cortical	thinning	and	enlargement	of	the	lateral	
cerebral	 ventricles.	 Reduced	 neuronal	 numbers	 in	 a	 variety	 of	 brain	 regions	 such	 as	 the	
temporal,	 parietal	 and	 enthorhinal	 cortex	 (Gomez-Isla	 et	 al.,	 1997),	 the	CA1	 region	of	 the	
























Tanzi	 et	 al.,	 1987),	 which	 is	 a	 single	 transmembrane	 glycoprotein	 consisting	 of	 an	
exocytoplasmic	 domain	 and	 a	 short	 cytoplasmic	 tail.	 This	 large	 precursor	 protein	 is	













This	 processing	 prevents	 an	 accumulation	 of	 Aβ	 peptides	 by	 demolishing	 the	 complete	
amyloid	 sequence.	 APP	 is	 sequentially	 cleaved	 by	 α-and	 훾-secretases	 to	 release	 a	 smaller	
fragment	(p3),	that	has	no	neuropathological	recognized	role.	The	α-site	cleavage	of	APP	by	
adamalysin	 protease	 (ADAM)	 cuts	 12-aa	 at	 the	 N-terminal	 single	 transmembrane	 domain	
(Roberts	 et	 al.,	 1994);	 consequently,	 a	 C-terminally	 truncated	 form	of	 soluble	 ectodomain	






Aβ	 protein	 is	 liberated	 by	 sequential	 proteolytic	 processing	 of	 APP	 involving	 β-and	 훾-
secretases.	 Initially,	proteolytic	 cleavage	occurs	16-aa	 residues	 to	 the	N-terminal	of	 the	α-
cleavage	site	by	the	β-site	APP	cleaving	enzyme	1	(BACE1)	(Hussain	et	al.,	1999;	Sinha	et	al.,	
1999;	Vassar	et	al.,	1999),	generating	a	soluble	amino	terminal	APP	derivate	(β-sAPP)	and	a	
membrane-associated	 99-residue	 C-terminal	 (C99,	 CTFβ).	 Further,	 훾-secretase	 activity	 at	
different	 intramembranous	CTFβ	sites	generates	Aβ	species	of	varying	 length	between	35-	
and	43-aa.	Foremost	among	them	are	peptides	of	Aβ40	or	Aβ42	aa	in	lengths,	that	are,	together	
with	 the	AICD,	most	 abundantly	 produced	 (Citron	 et	 al.,	 1995;	Haass	 et	 al.,	 1994;	 Selkoe,	
2001a;	Tang,	2009).	The	훾-secretase	is	a	highly	hydrophobic	catalytic	enzyme	and	composed	
of	distinct	components:	presenilin	proteins	(PS1	or	PS2),	nicastrin,	anterior	pharynx	defective	
1	 (APH1)	and	presenilin	enhancer	2	 (PEN-2).	Aside	of	being	 involved	 in	APP	processing,	훾-



























FBD	and	FDD	are	 late-onset	diseases	and	 clinically	 characterized	by	progressive	dementia,	
spastic	tetraparesis,	and	cerebellar	ataxia	(Mead	et	al.,	2000;	Stromgren	et	al.,	1970);	with	
neuropathological	hallmarks	similar	to	those	in	AD	including	severe	CAA,	neuroinflammation,	























2015;	 El-Agnaf	 et	 al.,	 2001).	Overexpression	of	 different	 amyloid	 peptides	 in	 the	 retina	of	
Drosophila	demonstrated	that	ADan	appears	to	be	more	toxic	compared	to	e.g.	Aβ42	peptides	
(Marcora	et	al.,	2014).	The	two	amyloidogenic	peptides,	ABri	and	ADan,	which	do	not	occur	in	
nature	 in	the	absence	of	 the	disease	causing	changes	 in	the	respective	precursor	proteins,	





formation	 and	 associated	 neurodegeneration.	 ABri	 and	 ADan	 therefore	 serve	 as	 principal	















Parkinson’s	 disease	 (PD)	 is	 characterized	 by	 tremors	 and	 locomotion	 abnormalities	 and	
constitutes	 the	 most	 frequent	 movement	 disorder	 among	 α-synucleinopathies	 including	
dementia	with	 Lewy	 body	 (DLB)	 and	Multiple	 System	Atrophy	 (MSA).	 PD	 is	 pathologically	
defined	 by	 the	 presence	 of	 aberrant	α-synuclein	 (α-Syn)	 in	 intracellular	 deposits	 of	 Lewy	















that	 C-terminal	 truncated	 α-Syn	 aggregates	 more	 rapidly	 compared	 to	 its	 full-length	
counterpart;	moreover,	truncated	α-Syn	species	exhibit	seeding	potential	of	full-length	α-Syn	
























Huntington’s	 disease	 (HD)	 is	 a	 late-onset,	 autosomal	 dominant,	 and	 progressive	
neurodegenerative	disorder	caused	by	a	CAG	trinucleotide	repeats	expansion	in	the	coding	
region	 of	 the	 huntingtin	 (htt)	 gene,	which	 encodes	 an	 polyglutamine	 (polyQ)	 stretch	 that	
alters	the	function	of	the	htt	protein;	indeed,	the	mutant	htt	possibly	affects	cellular	processes	
including	mitochondrial	dysfunction	and	vesicle	transport	failure	(Browne,	2008).	In	addition,	
















aggregation-prone	polyQ	 tract	 containing	N-terminal	 fragment,	 and	ultimately	 leading	 to	
intracellular	inclusions	and	neuronal	dysfunction	(Wellington	et	al.,	2000)	(Figure	1.10);	as	well	
as	 to	 impaired	mitochondrial	 trafficking,	preceding	the	 formation	of	aggregates	 (Orr	et	al.,	










Other	 trinuleotide	 repeat	 expansion	 disorders,	 including	 various	 forms	 of	 Spinocerebellar	
ataxia	 (SCA	 types	1,	2,	3,	6,	7,	 and	17)	and	Dentatorubral-pallidoluysian	atrophy	 (DRPLA)	
share	common	properties	of	HD,	albeit	being	 less	 frequent;	mutations	 in	polyQ	expansion	
alters	the	normal	function	of	ataxin	proteins	(Margolis	and	Ross,	2001;	Palhan	et	al.,	2005)	
and	 the	 transcription	 co-regulator	 atrophin-1	 (Sato	 et	 al.,	 2009),	 respectively,	 leading	 to	
intranuclear	aggregation	in	cerebellar	Purkinje	cells	and	cortical	neurons	(Rolfs	et	al.,	2003).	
Among	 the	 other	 types,	 an	 important	 neuropathological	 role	 of	 ataxin	 cleavage	 has	 been	
shown	in	a	Drosophila	model	of	SCA3	and	for	SCA7	 in	vitro	and	 in	vivo.	Specifically,	polyQ-
containing	 fragments	 derived	 from	 caspase-dependent	 cleavage	 of	 ataxin-3	 have	 been	
demonstrated	to	induce	neurotoxicity,	thus	contribute	to	SCA3	disease	progression	(Jung	et	
al.,	2009)		In	addition,	it	has	been	shown	that	toxic	polyQ-containing	fragments	generated	by	
caspase-7	 mediated	 N-terminal	 cleavage	 of	 ataxin-7	 are	 subject	 to	 regulated	 clearance	
mechanisms;	 however,	 distinct	 post-translational	 modifications	 such	 as	





















also	 manifest	 familial	 and,	 infectious	 forms.	 In	 human	 beings,	 prion	 diseases	 such	 as	
Creutzfeldt-Jakob	disease	(CjD)	and	kuru	are	clinically	characterized	by	progressive	dementia	
and	motor	dysfunction	(Prusiner,	1991).	
Prions	 are	 infectious,	 pathogenic	 proteins	 that,	 in	 contrast	 to	 viruses,	 are	 encoded	 by	 a	
chromosomal	 gene	 (PRNP)	 and	 are	 devoid	 of	 nucleic	 acid;	 they	 are	 crucially	 linked	 to	 the	
conversion	 of	 the	 physiological	 cellular	 prion	 protein	 (PrPC),	 a	 membrane-associated	
extracellular	glycoprotein	anchored	by	glycosylphosphatidylinositol	(GPI),	into	the	abnormal,	
self-propagating	‘scrapie’	prion	isoform	(PrPSc)	(Prusiner	et	al.,	1998).	The	post-translational	
modification	 from	a	 structural	 α-helical	 sheet	 to	 insoluble	 β-sheet	 structures	 results	 in	 an	



































oligomeric	species	 in	vitro	and	 in	vivo;	 indicating	that	the	structural	N-terminus	plays	a	key	
role	in	the	infectious	and	neurotoxic	process	(Trevitt	et	al.,	2014).	Moreover,	transgenic	mice	













TDP-43	proteinopathies	 including	 sporadic	 and	 familial	 frontotemporal	 lobar	degeneration	
(FTLD)	(Arai	et	al.,	2006)	and	amyotrophic	lateral	sclerosis	(ALS)	(Neumann	et	al.,	2006)	are	a	
group	of	 neurodegenerative	disorder	 caused	by	pathological	 neuritic	 inclusions	 containing	
transactive	response	(TAR)	DNA-binding	protein	43.	Aside	AD,	FTLD	is	the	most	common	form	
of	progressive	dementia	in	human	beings	under	the	age	of	65	years	(Neary	et	al.,	1998).	ALS,	











including	 alternate	 splicing,	 transcription,	 apoptosis,	 microRNA	 biogenesis,	 and	 mRNA	
transport	and	stability	(reviewed	in	Buratti	and	Baralle,	2008;	Ou	et	al.,	1995).	Human	TDP-43	
is	 a	 414-aa	 nuclear	 protein,	 ubiquitously	 expressed	 and	 highly	 conserved;	 structurally,	 it	
harbors	 two	 RNA-recognition	 motifs	 (RRM1;	 RRM2)	 and	 a	 protein-protein	 interaction	
mediating	 C-terminal	 glycine-rich	 region	 (Wang	 et	 al.,	 2004).	 Furthermore,	 the	 TDP-43	
molecule	exhibit	three	potential	caspase-3	cleavage	sites	(Zhang	et	al.,	2007).	
Both,	hyperphosphorylated	and	ubiquitinated	full-length	and	N-terminally	truncated	TDP-43	
are	 the	major	 component	 of	neuritic	 inclusions	 in	 brain	 tissue	 of	 FTLD	 and	 ALS	 patients.	
Caspase	 3/7-mediated	 proteolytic	 cleavage	 at	 Asp89	 and	 Asp220	 of	 wild-type	 TDP-43	
generates	a	35-kDa	(CTF35)	and	a	25-kDa	C-terminal	 fragment	 (CTF25)	 respectively	 (Figure	







remains	 elusive.	 However,	 several	 studies	 implicate	 a	 neurotoxic	 relevance	 of	 TDP-43	
fragmentation.	 Indeed,	 expression	of	caspase-cleaved	CTF25	 fragment	 in	human	cell	 lines	
lead	 to	cell	death	accompanied	by	 the	 formation	of	 toxic	 insoluble	aggregates;	aside,	 this	
fragment	did	not	interact	with	full-length	nuclear	TDP-43	or	affect	its	function,	thus,	indicating	
a	toxic	gain-of-function	(Zhang	et	al.,	2009b).	Furthermore,	this	fragment	showed	an	increased	
hyperphosphorylation	 propensity	 at	 sites	 not	 required	 for	 neurotoxic	 inclusion	 formation	
compared	to	full-length	TDP-43.	In	contrast,	another	study	demonstrated	that	TDP-43	CTFs	
provoke	both,	first,	the	formation	of	aberrant	phosphorylated	and	ubiquitinated	aggregates,	







cells	expressing	TDP-43	CTFs	cleaved	at	Arg208;	 thus,	 strengthened	the	pathogenic	 role	of	
TDP-43	fragments	in	FTLD	and	ALS	(Igaz	et	al.,	2009).	
However,	there	is	also	evidence	of	fragmentation-mediated	clearance	of	full-length	TDP-43:	
the	 activation	 of	 endoplasmatic	 reticulum	 (ER)	 membrane-bound	 caspase-4	 cleavage	
diminishes	ER	stress	caused	by	abundant	accumulation	of	TDP-43;	subsequent	activation	of	

























in	 aggregation	 prone	 fragments,	 pointing	 towards	 a	 general	 pathogenic	 role	 of	 protein	




specifically	 toxic	 entities.	 In	 most	 proteinopathies,	 the	 current	 evidence	 points	 towards	
considerable	neurotoxicity	of	early,	non-fibrillary	oligomeric	aggregates	(Berger	et	al.,	2007;	
Gerson	et	al.,	2014;	Patterson	et	al.,	2011;	Usenovic	et	al.,	2015).	This	concept	of	oligomer	




























Protein	 fragmentation	 is	 increasingly	emerging	as	an	 integral	event	 in	 the	pathogenesis	of	
neurodegenerative	diseases.	Numerous	in	vitro	and	in	vivo	studies	have	addressed	whether	
cleavage	of	disease-associated	proteins	is	sufficient	to	exacerbate	an	ongoing	disease	process.	
Indeed,	 the	 relevance	 of	 protein	 fragmentation	 has	 been	 highlighted	 in	 the	 course	 of	 a	
plethora	 of	 proteinopathies	 with	 an	 emphasis	 on	 the	 neurotoxic	 potential	 of	 protein	

























Aβ	 species	 has	 been	 demonstrated	 (Langer	 et	 al.,	 2011);	 thus	 indicating	 that	 Aβ	 species	
present	in	the	CSF	may	exhibit	similar	seed-like	properties	in	vivo.	
	












































































































































(a-c)	 Overview	 on	 the	 transgenic	 and	 co-transgenic	mouse	 lines	 used	 for	 the	 present	 studies.	 Tau	 isoforms	
expressed	are	shown.	Dark	grey	boxes	indicate	the	tau	repeat	domains	(3R	or	4R	isoforms),	and	light	grey	boxes	
N-terminal	inserts	(e.g.	ALZ17		2N4R).		
The	 tau	 cDNA	 constructs	 are	 either	 driven	 by	 a	 standard	 Thy1.2	minigene	 (Thy1.2)	 or	 by	 a	modified	 Thy1.2	
minigene	 that	 contains	 a	 tetracycline	 controlled	 transcriptional	 silencer	 element	 (Thy1.2-tTS)	 in	 case	 of	 the	





































the	 high	molecular	 weight	 tau	 species.	 (d)	 Sarkosyl-extraction	 detects	 only	 soluble	 tau	 species	 in	 paralyzed	
P301SxTAU62on	 mice	 (“sol”:	 sarkosyl-soluble	 tau;	 “insol”:	 sarkosyl-insoluble	 fraction).	 (e-g)	Dtau	 was	 widely	
expressed	 in	 the	 spinal	 cord	 of	 P301SxTAU62on	 mice	 (e)	 and	 phosphorylated	 at	 the	 AT8	 epitope	 (f).	 Upon	













(a-f),	 synaptophysin	 (g-i),	 VAMP2	 (k-m),	 and	 cytochrome	C	oxidase	 (COX)	 (n-p),	 in	 the	hippocampus	of	 non-
transgenic	mice	(B6),	3-week-old	paralyzed	mice	(P301SxTAU62on)	and	recovered	mice	6	weeks	after	cessation	
of	Dtau	expression	(P301SxTAU62on-off).	The	scale	bar	in	a	corresponds	to	19	µm	in	d-f,	63	µm	in	a-c	and	g-i,	and	












immunohistochemistry	 using	 2f11	 antibody	 (c).	 The	 scale	 bar	 in	 c	 corresponds	 to	 30	 µm	 in	 a-c.	 (d-g)	 M.	
gastrocnemius	stained	for	ATPase	(pH	4.2).	Dark	type	1	fibres	(1)	and	light	type	2	fibres	(2).	The	scale	bar	in	g	














after	cessation	of	Dtau	expression)	ALZ31xTAU62	mice	 (see	also	video	S6).	 (b)	Absence	of	 recovery	of	motor	
function	as	assessed	by	a	grid-test	of	ALZ31xTAU62	mice	following	the	removal	of	doxycycline	between	14	and	
16	days	(blue	line;	triangles	indicate	the	times	of	euthanasia,	n=6).	Motor	function	of	heterozygous	ALZ31	mice	











































































Synaptophysin	 synaptophysin	 IHC	1:1000	 Millipore	Corporation,	Billerica,	MA	
#MAB5258	







GAPDH	(6C5)	 GAPDH	 WB	1:1000	 Santa	Cruz	Biotechnology,	Santa	Cruz,	CA,	
#32233	




















Protective	 effect	 of	 early	 tau	 burden	 on	 late	 neurotoxic	





















































tau	 pathology	 in	 later	 stages,	 ultimately	 manifesting	 in	 earlier	 tau	 tangle	 formation.	
Interestingly,	 compared	 to	 their	 heterozygous	 P301S	 tau	 transgenic	 littermates	 that	 have	
never	been	paralyzed,	recovered	P301SxTAU62on-off	mice	that,	in	contrast,	experienced	early	





















age	 of	 12	months,	 as	well	 as	 no	 differences	 in	 sex-specific	 bodyweight	were	 found	 at	 16	
months	of	age	(Figure	3.1	d,	e	and	f).	
	
            	
	



































































contrast	 to	 their	 heterozygous	 P301S	 transgenic	 littermates,	 P301SxTAU62on-off	 mice	 exhibit	 a	 better	 grid	
reflex,	motor	strength	and	motor	coordination	at	ages	of	12,	14,	and	16	months.	(a-c)	Pathological	hind	limb	
spreading	was	assessed	by	a	tail	suspension	test.	(a)	Paralyzed	P301SxTAU62on	mice	at	age	of	3	weeks	exhibit	































Furthermore,	 in	 line	with	 these	 histopathological	 findings,	 anti-tau	 antibody	 AT8	 revealed	
attenuated	 tau	 hyperphosphorylation	 in	 P301SxTAU62on-off	 mice	 when	 compared	 to	 their	
Figure	3.2.	Formerly	paralyzed	P301SxTAU62on-off	mice	reveal	significant	less	tau	pathology.	Compared	to	their	
heterozygous	P301S	littermates,	P301SxTAU62on-off	mice	that	underwent	severe,	early	tau	stress	remain	almost	
devoid	 of	 tau	 tangle	 pathology	 in	 the	 brainstem	 and	 exhibit	 attenuated	 tau	 hyperphosphorylation.	 (a	 -	 d)	























levels	 correspond	 to	 the	 present	 histopathological	 phenotypes	 in	 formerly	 paralyzed	
P301SxTAU62on-off	mice	and	their	heterozygous	P301S	mutant	littermates.	Through	Western	
Blot	 analysis,	we	 confirmed,	 as	expected,	 a	 significant	 reduction	 in	both	 the	 total	 tau	and	
sarkosyl-soluble	 tau	expression	 level	 in	P301SxTAU62on-off	mice	 (Figure	3.3	a-d);	notably,	 in	
heterozygous	 P301S	 littermates,	 the	 marked	 histopathological	 tau	 tangle	 pathology	 is	


























































































12)	mice	 (a	 and	 c);	 GAPDH	 staining	 was	 used	 for	 protein	 normalization	 (b	 and	d).	 At	 the	 age	 of	 16	months,	






































































































































































































































App23	 tg	CSF	 18	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 24	 14	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 18	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 tg	CSF	 24	 21	
App23	 wt	CSF	 3	 21	
App23	 wt	CSF	 24	 21	
App23	 wt	CSF	 24	 21	
App23	 FB	 24	 20	
App23	 FB	 24	 20	
C57BL6	 tg	CSF	 24	 21	
C57BL6	 tg	CSF	 18	 21	
C57BL6	 tg	CSF	 18	 21	
App23	 conc.	 tg	CSF	 24	 11	
App23	 conc.	 wt	CSF	 24	 11	
App23	 conc.	 tg	CSF	 24	 20	
 





















Sample	 Aβ40,	pg/μl	CSF	 sAPPα,	pg/μl	CSF	 sAPPβ,	pg/μl	CSF	
APP23	CSF	 4.2	 92	 121	












APP23	 tg	CSF	 14	 4	 0.77	 0.94	 1.15	 0.56	
APP23	 tg	CSF	 21	 5	 0.79	 0.91	 1.05	 0.19	
APP23	 wt	CSF	 21	 3	 0.65	 0.81	 1.01	 0.06	
APP23	 FB	 20	 2	 0.41	 0.54	 0.70	 0.00***	
C57BL6	 tg	CSF	 21	 3	 0.00	 0.00	 0.00	 NA	
APP23	 conc.	 tg	CSF	 11	 1	 0.59	 0.88	 1.30	 0.52	
APP23	 conc.	 wt	CSF	 11	 1	 0.72	 1.10	 1.67	 0.66	
APP23	 conc.	 tg	CSF	 20	 1	 0.61	 0.92	 1.40	 0.70	
 
Table	S3.	Geometric	mean	ratios	(GMR)	of	amyloid-β	ratios	comparing	non-injected	vs	injected	hippocampus.	
























Alzheimer’s	 disease	 represents	 the	 most	 prevalent	 form	 of	 a	 major	 subclass	 of	 various	
neurodegenerative	diseases:	the	tauopathies.	In	Switzerland	alone,	over	100’000	people	are	
estimated	to	suffer	from	dementia	including	AD;	and	this	number	is	expected	to	triple	by	2050	
(Blankman	et.al,	 2012).	 To	date,	 the	 lack	of	 therapeutic	 treatments	 limits	pharmacological	
therapies	 to	 symptomatic	 interventions	 and	 given	 that	 millions	 of	 people	 have	 been	
diagnosed	 worldwide,	 AD	 constitutes	 a	 crucial	 source	 of	 social	 and	 economic	 problems	
(Scheltens	et	al.,	2016).	
The	disease	spectrum	in	patients	with	neurodegenerative	disorders	including	AD	extends	from	
genetic	 alterations	 to	 protein	 modifications	 and	 altered	 inner	 life	 of	 a	 cell	 in	 affected	
anatomical	 regions	 through	 to	 clinical	 manifestations.	 Years	 of	 research	 has	 led	 to	 the	
discovery	 of	 a	 plethora	 of	 proteins	 being	 crucial	 in	 the	 course	 of	 neurodegenerative	
syndromes;	but	ever	since	researchers	are	puzzled	by	pieces	of	the	big	picture.	The	cleavage	
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In	human	 tauopathies,	 the	distinct	molecular	 and	 cellular	mechanisms	 contributing	 to	 the	
pathogenesis	and	progression	of	tauopathies	remain	still	opaque.	Precisely,	 the	 initiator	of	
neurotoxic	events	and	how	neurotoxicity	 is	mediated	 is	not	known	 in	detail.	Aside	 the	Aβ	
peptide	 and	 its	 pathological	 role	 in	 AD,	 the	 closer	 correlation	 between	 tau	 and	 disease	
progression	arouse	attention	and	promoted	tau-focused	research.	Thus,	the	development	of	
transgenic	 mouse	 models	 allowed	 to	 investigate	 core	 aspects	 of	 the	 pathogenesis	 of	
tauopathies	 by	 modeling	 particular	 disease	 steps	 in	 vivo;	 ultimately	 aiming	 for	 a	 better	





The	 neuropathological	 identity	 of	 AD	 falls	 into	 two	 broad	 categories:	 extracellular	 senile	





expression	 of	mutant	 human	 tau	 protein,	 transgenic	mouse	models	 were	 generated	 that	
exhibit	 distinct	 aspects	 of	 tau	 pathology	 such	 as	 age-related	 filamentous	 tau	 deposits,	
neuronal	degeneration	and	axonal	transport	dysfunction	(Gotz	et	al.,	2004).	
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toxic	tangle	formation	and	facilitate	and	promote	tau	aggregation	compared	to	full-length	tau	
species	 (Abraha	 et	 al.,	 2000;	 Berger	 et	 al.,	 2007;	 Cowan	 et	 al.,	 2010).	 Various	 proteases	
including	caspase	3,	caspase	6	and	calpains	have	been	identified	to	cleave	full-length	tau	into	
fragments	 which	 accumulation	 correlates	 with	 the	 progression	 of	 AD;	 notably,	 D421	




a	 short,	 human	 3R	 tau151–421	 fragment	 (Δtau)	 that	 develop	 a	 mildly	 progressive	 motor	
phenotype	with	ataxia	at	about	18	months	of	age.	Interestingly,	TAU62	mice	did	not	develop	









in	our	own	novel	mouse	model	 co-expressing	 truncated	and	 full-length	 tau	 (Ozcelik	et	 al.,	
2016).	 In	 line	with	 this,	we	 set	 out	 to	 complete	 the	 neuropathological	 characterization	 of	
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First,	we	 generated	double	 transgenic	 P301SxTAU62on	mice	 co-expressing	Δtau	 and	P301S	
mutant	 0N4R	 tau.	 Aside,	 full-length	 tau	 expressing	 human	 mutant	 P301S	 heterozygous	
transgenic	mice	develop	insoluble	tau	filaments	and	paralysis	around	12	months	of	age	(Allen	











could	 confirm	 the	 reversibility	 of	 Δtau	 induced	 neuronal	 dysfunction	 in	 severely	 affected	
P301SxTAU62on	 mice.	 When	 only	 Δtau	 expression	 was	 halted,	 former	 paralyzed	
P301SxTAU62on-off	 mice	 rapidly	 regained	 full	 motor	 control	 and	 re-established	 nerve	 fiber	
function	 and	 restored	 muscle	 fiber	 atrophy	 was	 observed.	 Moreover,	 the	 functional	 and	
structural	recovery	was	paralleled	by	the	disappearance	of	oligomeric	tau	species.	
Second,	given	the	artificial	nature	of	P301S	mutant	tau,	we	aimed	for	an	 in	vivo	analysis	of	
Δtau	 in	presence	of	 full-length	wild-type	tau.	 Indeed,	we	could	 reproduce	the	pronounced	
reversible	 neurotoxicity	 in	 double	 transgenic	 ALZ17xTAU62on	mice	 co-expressing	 Δtau	 and	
full-length	wild-type	2N4R	tau.	
Third,	we	analyzed	TAU62xALZ31on	mice	expressing	3R	Δtau	and	the	shortest	form	of	wild-




Of	 note,	 co-expression	 of	 only	 full-length	 tau	 species	 was	 not	 sufficient	 to	 induce	 severe	
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Overall,	these	findings	highlight	two	essential	aspects	of	tauopathies:	tau	fragmentation	and	





species	 contributing	 to	 the	 neurodegenerative	 process	 in	 tauopathies;	 in	 fact,	 tau	 toxicity	
precedes	the	formation	of	 insoluble	aggregates	 in	our	mouse	model	and	thus	 fibrillary	tau	
formation	 appears	 to	 be	 not	 required	 for	 tau	 toxicity,	 similar	 to	 findings	 in	 other	






The	neurotoxic	potential	 of	 protein	 fragments	 in	 the	 course	of	 various	neurodegenerative	
disorders	 remains	 to	 be	 established	 in	 detail.	 However,	 neurodegeneration-associated	
proteins	 are	 substrate	 to	 various	 proteolytic	 enzymes	 that	 cleave	 designated	 proteins	 at	
individually	different	sites	(Figure	4.1).	The	neurotoxic	effect	of	protein	fragments	has	been	
shown	i.e.	for	the	intramebranous	located	APP	(Selkoe,	2001a),	the	transmembranous	located	
BRI2	 (Rostagno	and	Ghiso,	 2008;	Vidal	 et	 al.,	 1999;	Vidal	 et	 al.,	 2000),	 intracellular	 and/or	
extracellular	cleaved	α-Syn	(Dufty	et	al.,	2007;	Kim	et	al.,	2012;	Mishizen-Eberz	et	al.,	2005)	,	
intracellular	cleaved	htt	(Graham	et	al.,	2006;	Waldron-Roby	et	al.,	2012;	Wellington	et	al.,	
2002)	 and	 ataxins	 (Guyenet	 et	 al.,	 2015;	 Hubener	 et	 al.,	 2013;	 Mookerjee	 et	 al.,	 2009),	
membrane	anchored	PrP	(Altmeppen	et	al.,	2012;	Trevitt	et	al.,	2014),	and	nuclear	TDP-43	
(Furukawa	 et	 al.,	 2011;	 Nonaka	 et	 al.,	 2009).	 Across	 the	 different	 neurodegenerative	
disorders,	major	enzymes	involved	in	the	proteolytic	processes	are	caspases	and	calpains;	in	
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In	light	of	this,	inhibition	of	caspases	and	calpains	cleavage	emerged	as	a	potential	target	to	
prevent	 disease	 pathology	 and	might	 be	 a	 promising	 therapeutic	 strategy	 considering	 the	
observed	 neurotoxicity	 in	 our	mouse	model.	 Indeed,	 calpain-specific	 inhibitors	 have	 been	
shown	to	attenuate	AD-like	pathology	in	3xTgAD	mice	(Medeiros	et	al.,	2012);	further	reduce	
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Targeting	toxic	oligomeric	tau	species	
	








cascade	of	 tau	pathology	 leading	 to	neuronal	 loss	 (Blair	et	al.,	2013;	Brunden	et	al.,	2008;	
Gerson	 and	 Kayed,	 2013;	 Gerson	 et	 al.,	 2014;	 Usenovic	 et	 al.,	 2015).	 Indeed,	 progressive	
neuronal	 degeneration	 in	 absence	 of	 tau	 filament	 formation	 was	 reported	 not	 only	 in	
tauopathy	mouse	models	 (Oddo	 et	 al.,	 2003;	 Spires	 et	 al.,	 2006;	 Sydow	 and	Mandelkow,	
2010),	 but	 also	 in	 tau	 transgenic	 drosophila	models	 (Cowan	et	 al.,	 2010;	Wittmann	 et	 al.,	
2001).	Aside,	oligomeric	protein	species	have	been	implicated	in	the	pathogenesis	of	various	
neurodegenerative	diseases:	 in	brains	of	AD	patients,	 oligomeric	Aβ	peptides	 appeared	 to	
participate	in	the	neurotoxic	cascade	even	before	the	onset	of	symptoms	(Lesne	et	al.,	2013);	








Oligomeric	 tau	 species	 are	 considerably	 interesting	 as	 a	 potential	 immune	 target.	 The	
observed	severe	neurotoxicity	associated	with	abundant	tau	oligomer	formation	suggests	our	
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mitigate	 tau	 aggregation	 in	 P301L	 transgenic	mice	 (Asuni	 et	 al.,	 2007).	Moreover,	 passive	
immunization	 approaches	 with	 anti-tau	 directed	 monoclonal	 antibodies	 were	 shown	 to	
reduce	 tau	pathology,	when	administrated	prior	 to	 the	disease	onset	 (Boutajangout	et	al.,	
2011;	Chai	et	al.,	2011).	However,	the	rapid	onset	of	tau	toxicity	in	our	mouse	model	favours	





Here	we	report	that	 fragmented	tau	exacerbates	the	toxicity	of	 full-length	tau	 in	vivo.	Our	
mouse	model	exhibit	pronounced	drastic,	but	remarkably,	reversible	toxic	effect	of	oligomeric	
tau	 species	 associated	 with	 extensive	 neuronal	 dysfunction	 and	 a	 severe	 neurological	
phenotype.	 In	 P301SxTAU62on	 mice,	 apparent	 mitochondrial	 dislocation	 and	 clumping,	
disruption	 of	 the	 Golgi	 network	 and	 missorting	 of	 synaptic	 proteins	 strongly	 suggests	 a	
widespread	disruption	of	the	cellular	transport	system	(Kopeikina	et	al.,	2011;	Liazoghli	et	al.,	
2005).	 Interestingly,	 comparable	 perinuclear	 mitochondrial	 clumping	 associated	 with	 the	
presence	 of	 only	 soluble	 tau	 species	was	 reflected	 in	 studies	 on	 rTg4510	 transgenic	mice	
(Kopeikina	et	al.,	2011).	Fragmentation	of	the	Golgi	apparatus	(GA)	disturbs	the	central	sorting	
machinery	for	all	newly	synthesized	proteins	destined	for	fast	axonal	transport	and	is	believed	






and	 degradation	 of	 VAMP2,	 a	 binding	 partner	 of	 synaptophysin,	 indicate	 congested	 Golgi	

















in	 the	 dynamically	 assembly	 and	 stability	 of	 this	 cytoskeleton	 component;	 and	 thus,	
instrumental	 for	 viability	 of	 the	 intracellular	 transport	 system	 (Kosik,	 1993).	 However,	
modifications	of	tau	are	likely	responsible	for	the	dysregulation	of	the	microtubule	network.	
There	are	two	possible	explanations	for	the	disruption	of	polarized	microtubule	tracks:	one	
source	 of	 interference	 might	 constitute	 abnormal	 high	 levels	 of	 tau	 and	 its	 concomitant	




of	 benefit	 for	 the	microtubule	 network	 operability.	Of	 note,	 co-expression	 of	 various	 full-
lengths	forms	of	tau	in	our	P301SxALZ31	and	ALZ17xALZ31	revealed	comparable	levels	of	tau	
hyperphosphorylation,	 without	 a	 pronounced	 motor	 phenotype;	 thus,	 tau	




























2016).	Based	on	our	 results,	we	 set	out	 to	 investigate	 the	 long-term	consequences	of	 the	
extensive	neurotoxic	stress	during	early	postnatal	life	in	formerly	paralyzed	P301SxTAU62on-
off	mice.	Remarkably,	we	found	that	these	mice	exhibit	a	less	pronounced	motor	phenotype	
at	14	 to	16	months	of	age	compared	to	 their	heterozygous	P301S	 littermates	 that	did	not	
experience	compelling	neurotoxicity	early	in	life.	This	is	paralleled	by	significant	reduced	tau	
pathology	 in	 aged	 P301SxTAU62on-off	 mice:	 the	 histopathological	 phenotype	 of	 formerly	
paralyzed	mice	showed	mitigated	tau	hyperphosphorylation	and	almost	no	signs	of	insoluble	




underlying	 delayed	 tau	 pathology	 in	 P301SxTAU62on-off	 mice.	 As	 aforementioned,	 various	
active	 immunization	attempts	using	recombinant	tau	peptides	have	been	shown	to	reduce	
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oligomeric	or	hyperphosphorylated	tau	from	the	cell.	For	instance,	cytosolic	proteases	such	







effects	 of	 early	 tau	 stress	 in	 P301SxTAU62on-off	mice	 could	 point	 towards	 the	 induction	 of	
autophagic	pathways	 in	general.	The	 removal	of	aggregation-prone	proteins	 through	basal	
autophagy	has	been	shown	to	be	of	importance	for	cell	survival;	indeed,	the	consensus	in	the	






protein	 Atg9,	 which	 controls	 the	 formation	 of	 phagophore	 in	 the	 process	 of	 autophagy,	
through	Rab1a	inhibition;	however,	Rab1a	overexpression	has	been	shown	to	reverse	α-Syn	
induced	autophagy	impairment	(Winslow	et	al.,	2010).	In	addition,	stimulation	of	insulin	and	
insulin-like	growth	 factor	1	 signaling	 cascades	 results	 in	 increased	autophagic	 clearance	of	





a	 restored	 autophagic	 flux	 associated	 with	 reduced	 accumulation	 of	 autophagy	 related	
proteins	p62	and	LC3	in	P301S	mutant	mice	(Ozcelik	et	al.,	2013;	Schaeffer	et	al.,	2012).	Of	
note,	 microtubule-associated	 protein	 1	 light	 chain	 3	 protein	 (LC3)	 is	 required	 in	 the	
autophagosome	formation	process	(Mizushima	and	Komatsu,	2011);	and	p62	is	an	ubiquitin-
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(Fritschi	 et	 al.,	 2014).	 Here	 we	 set	 out	 to	 inoculate	 forebrain	 homogenate	 or	 CSF	 in	 the	
hippocampus	of	APP23	transgenic	mice,	and	analyse	the	seeding	effect	of	Aβ	in	the	CSF	and	
brain.	Consistent	with	this	previous	report,	we	found	that	Aβ	species	in	brain	homogenates	





in	 the	 CSF.	 Whereas	 small	 and	 soluble	 Aβ	 species	 derived	 from	 APP23	 mice	 have	 been	
demonstrated	to	be	highly	seed-potent	(Langer	et	al.,	2011),	these	Aβ	species	appear	not	to	
be	present	in	the	CSF;	possibly	due	to	downregulated	transport	to	the	CSF	compartment,	or	















tauopathies.	 This	 information	 is	 in	 line	 with	 the	 neurotoxic	 potential	 of	 protein	 cleavage	


















































Inducible	 and	 neuron-specific	 3R	 tau151–421	 (Δtau)	 expressing	 TAU62	 mice	 were	
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1.2	promoter	by	a	tetracycline	controlled	transcriptional	silencer	element	(tTS).	The	Thy	
1.2-TRE-Δtau	 construct	 contained	 a	 tetracycline	 responsive	 element	 (TRE)	 800bp	
upstream	of	the	human	wild-type	Δtau	cDNA	encoding	amino	acids	151	to	421	of	a	3-
repeat	domain	spanning	human	wild-type	tau	fragment	(0N3R	tau151-421).	A	total	of	six	
positive	 transgenic	 founder	 TAU62	 mice	 (C57BL/6J-TgN(tTS-Thy1-Δtau151-421)	 were	
identified	and	the	inducible	expression	of	human	Δtau	was	assessed	by	western	blot	and	







The	 production	 of	 P301S	 mutant	 0N4R	 tau	 transgenic	 mice	 (C57BL/6J-TgN	 (Thy1	
hTauP301S))	has	been	previously	described	(Allen	et	al.,	2002).	Mice	were	generated	by	
subcloning	P301S	mutated	cDNA	encoding	the	shortest	human	four-repeat	tau	isoform	
(383	amino	acids	 isoforms	of	human	 tau)	 into	 a	murine	Thy	1.2	 genomic	expression	
vector	using	XhoI	restriction	site.	Transgenic	mice	were	generated	by	microinjection	into	
pronuclei	of	(C57BL/6J	x	CBA/ca)	F1	generation.	PCR	analysis	was	performed	to	identify	
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5.1.10 ALZ17xALZ31	mice	
	




















(EtOH).	After	 the	solution	was	centrifuged	again	 (13000	rpm,	10	min),	 the	remaining	
DNA	pellet	was	dried	on	Eppendorf	Thermomixer	comfort	shaker	(55°C,	5-10	min)	and	
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5.3.1 Tissue	 preparation	 and	 processing:	 Brain,	 Spinal	 cord	 and	 Sciatic	
nerve	
	
After	 perfusion,	 the	 spinal	 cord,	 sciatic	 nerve	 and	 the	 brain	 were	 quickly	 removed,	
immersion	fixed	in	4%	paraformaldehyde	O/N,	and	embedded	in	paraffin.	Brains	were	
cut	either	sagittally	(4–20	μm	transverse	serial	sections)	or	in	coronal	plane	anterior	to	















incubated	 with	 ImmPRESTM	 Reagent	 peroxidase	 for	 anti-mouse	 antibody	 (Vector	
Laboratories,	 USA)	 for	 1h	 at	 RT.	 After	 the	 incubation,	 sections	 were	 washed	 with	
































(2	 min)	 and	 incubated	 in	 1%	 Alkaline	 Silver	 solution	 (1M	 sodium	 hydroxide;	 0.6M	
potassium	iodide;	1%	silver	nitrate	solution;	all	from	Merck,	Germany),	for	10	min	at	RT.	
After	 incubation	 in	 ABC	 solution	 and	 simultaneous	monitoring	 of	 the	 reaction	 time,	







Solution	 Composition	 Concentration	 Supplier	


























































washed	 in	dH2O	 (3x)	and	 incubated	 in	 impregnation	 solution	at	37°C	O/N.	Next	day,	
sections	 were	 placed	 onto	 filter	 paper	 to	 remove	 superfluous	 fluid	 and	 transferred	
directly	in	reduction	solution	for	10	min.	The	sections	were	then	washed	in	tap	water	(5	
min)	and	placed	in	dH2O.	After,	the	sections	were	moved	in	0.25%	Gold	chloride	solution	





(2x)	 to	 remove	 excess	 stain,	 then	 placed	 in	 running	 cold	 tap	 water	 for	 5	 min	 and	
transferred	 into	 dH2O.	 Slides	 then	 were	 placed	 in	 0.1%	 Lithium	 carbonate	 for	 few	
seconds	and	distained	in	70%	EtOH	before	to	be	washed	in	dH2O.	Finally,	the	slides	were	

























































After	 perfusion,	 gastrocnemius	 (GC),	 soleus	 (Sol),	 tibialis	 anterior	 (TA)	 and	 extensor	
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dH2O	before	transferring	in	2%	Cobalt	Chloride	for	5	min.	After	washing	in	tap	water	
(3x),	the	sections	were	placed	in	Ammoniumsulfide	solution	(14	sec)	and	rinsed	before	






followed	 by	washing	 samples	 in	 10	mM	 PBS	O/N.	 The	 tissues	were	 reduced	 in	 1	%	
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The	tissues	were	reduced	in	1	%	Osmium	tetroxide	and	1.5%	Potassium	Ferrocyanide	
for	40	min;	after,	the	tissues	were	transferred	in	1%	Osmiumtetroxid	for	40	min.	The	
tissues	 were	 dehydrated	 as	 previously	 described	 and	 embedded	 in	 Epon.	 During	
dehydration,	 the	 sections	were	 treated	with	 1%	 uranyl	 acetate	 in	 70%	 EtOH	 for	 1h.	





























































samples	 were	 further	 centrifuged	 at	 80	 000g	 (28	 000	 rpm)	 for	 15	 min	 by	 using	










































acetate	 gel.	 Gels	 were	 run	 first	 at	 100V	 for	 30	min,	 then	 subsequently	 at	 120V	 for	
additional	60	min.	After	the	removal	of	gels	from	the	cassette	and	activation	of	PVDF	
membrane	 (Amersham	Biosciences)	 for	 first,	 30	 sec	 in	methanol	 and	 then,	 5	min	 in	
transfer	buffer,	samples	were	transferred	on	the	PVDF	membrane	at	30V	for	2h	by	using	
the	XCell	IITM	Blot	Module.	Next,	Unspecific	binding	epitopes	were	blocked	with	5%	non-




again	 in	PBS-T	 (3x5	min)	 at	RT	 and	detected	by	electrochemiluminescence	 (ECL)	 (GE	
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5.6 Antibodies	
	











































Synaptophysin	 synaptophysin	 IHC	1:1000	 Millipore	Corporation,	Billerica,	MA	
#MAB5258	








GAPDH	(6C5)	 GAPDH	 WB	1:1000	 Santa	Cruz	Biotechnology,	Santa	Cruz,	
CA,	#32233	














































Grid	 reflex	 and	motor	 strength	of	mice	was	 assessed	by	 the	 grid	 test.	Animals	were	






































All	 statistical	 analysis	was	performed	using	one-way	analysis	of	 variance	 followed	by	
Bonferroni’s	 multiple	 comparison	 test	 and	 Student’s	 t-tests	 with	 GraphPad	 Prism	
Software	Version	5.0a	(GraphPad	Software,	La	Jolla,	CA,	USA).	P-values	are	established	
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PCs	
PD	
PEN-2	
PGRN	
PHF	
PiD	
PK	
PolyQ	
PP	
PRNP	
PrPC		
PrPSc	
PRR	
PS1/2	
PSA	
PSP	
RRM	
sAPP	
SAA	
SCA	
SH3	
SPPL2	
TARDBP	
TDP-43	
TRD	
TTR	
UPS	
tTs		
VAMP2	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
 
	
	
proprotein	convertases	
Parkinson’s	disease	
presenilin	enhancer	2	
progranulin	
paired	helical	filaments	
Pick’s	disease	
protein	kinase	
Polyglutamine	disease	
phosphatase	
PRioN	Protein	
cellular	prion	protein 
scrapie	prion	protein	
pronline-rich	region	
presenilin	1	and	2	
puromycin-sensitive	aminopeptidase	
progressive	supranuclear	palsy	
RNA-recognition	motifs	
soluble	ectodomain	of	APP	
serum	amyloid	A	
spinocerebellar-ataxia	
SCR	Homology-3	
signal	peptide	peptidase-like	2	
transactive	response	DNA	binding	protein	
transactive	response	DNA	binding	protein	43	kDA	
Trinucleotide	repeat	expansion	disorder	
Globular	protein	transthyretin	
ubiquitine	proteasome	system	
tetracycline	controlled	transcriptional	silencer	element	
vesicle	associated	membrane	protein	
 
